What is ALK?
ALK, or anaplastic lymphoma kinase, accounts for about 4% of lung cancer patients. ALK inhibitors can work very, very effectively in that subset of patients, where their tumors are driven by ALK.
What other biomarkers have been identified?
In addition to ALK, other biomarkers have been identified and some treatments that “target” these biomarkers have been approved or are currently in clinical trial.
This chart shows current discoveries: